Meds Apotek AB

As of June 30, 2026, Meds Apotek AB carries a market capitalization of 404.87M, placing it among publicly traded companies globally. Its enterprise value stands at 340.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Meds Apotek AB's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Meds Apotek AB has 18.57M shares outstanding.

As of June 30, 2026, Meds Apotek AB trades at a trailing price-to-earnings ratio of 26.63. The price-to-sales ratio is 0.37, and the price-to-book ratio stands at 2.91.

As of June 30, 2026, Meds Apotek AB trades at an EV/EBITDA multiple of 14.65 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 73.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 340.60M versus a market cap of 404.87M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Meds Apotek AB maintains a current ratio of 1.75, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.71, indicating elevated leverage, while an interest coverage ratio of 44.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Meds Apotek AB recorded an income tax benefit of -10.29M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 4.67M, leaving 14.96M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Meds Apotek AB's stock has declined approximately 58.49% over the past 52 weeks. The 50-day moving average sits at 24.43, while the 200-day moving average is 28.84.

Over the twelve months ended June 30, 2026, Meds Apotek AB generated 1.08B in revenue and converted that into 14.96M in net income, yielding earnings per share of 0.80. EBITDA reached 23.26M, while operating income came in at 4.65M.

As of June 30, 2026, Meds Apotek AB holds 66.66M in cash and equivalents against 2.38M in total debt, resulting in a net debt position of -66.65M. Total book value stands at 139.31M, with working capital of 100.39M providing operational flexibility.

Meds Apotek AB produced 13.56M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.86M in capital expenditures, free cash flow totaled 702,000.00 - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Meds Apotek AB posted a gross margin of 27.27, reflecting its pricing power and cost economics. The operating margin of 0.43 and net profit margin of 1.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.17, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -12.73, meaning Meds Apotek AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Meds Apotek AB has an Altman Z-Score of 3.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.